Notably, pharmacological inhibition of lipid peroxidation through targeting GPX4 or ACSL4 has been shown to overcome tumor resistance to immunotherapy and improve clinical outcomes, thereby presenting a promising strategy for developing combinatorial treatment regimens [318,322]. Here, GPX4 is linked to neoplasm.